🇨🇳#TAL #трейд
Morgan Stanley, UBS Asset Management Americas, и BlackRock увеличились в TAL Education
Morgan Stanley grew its holdings by 9.5%. It now owns 59,547,935 shares of the company’s stock worth $3,206,655,000.
UBS Asset Management Americas Inc. now owns 58,795,227 shares of the company’s stock valued at $4,204,447,000.
BlackRock now owns 19,652,819 shares
Morgan Stanley, UBS Asset Management Americas, и BlackRock увеличились в TAL Education
Morgan Stanley grew its holdings by 9.5%. It now owns 59,547,935 shares of the company’s stock worth $3,206,655,000.
UBS Asset Management Americas Inc. now owns 58,795,227 shares of the company’s stock valued at $4,204,447,000.
BlackRock now owns 19,652,819 shares
🇺🇸#PFE
Pfizer работает над версией вакцины против штамма Дельта
PFIZER SAYS PLAN TO START IMMUNOGENICITY AND SAFETY STUDY IN AUGUST TO EVALUATE UPDATED VERSION OF COVID-19 VACCINE DESIGNED TO TARGET THE DELTA VARIANT
Pfizer работает над версией вакцины против штамма Дельта
PFIZER SAYS PLAN TO START IMMUNOGENICITY AND SAFETY STUDY IN AUGUST TO EVALUATE UPDATED VERSION OF COVID-19 VACCINE DESIGNED TO TARGET THE DELTA VARIANT
🇺🇸#TSLA
Tesla внесет серьезные изменения в свою розничную стратегию - Electrek
компания уйдет от выставочных залов в модных торговых центрах и вместо этого сосредоточится на более дешевых местах, удаленном управлении парком тест-драйвов и центрах доставки.
Tesla внесет серьезные изменения в свою розничную стратегию - Electrek
компания уйдет от выставочных залов в модных торговых центрах и вместо этого сосредоточится на более дешевых местах, удаленном управлении парком тест-драйвов и центрах доставки.
⚡️🇺🇸#MCD #отчетность
McDonalds Q221 Earnings:
Revenue: USD5.89B (est USD5.57B)
Adj EPS: USD2.37 (est USD2.11)
Comp Sales: +40.5% (est +38.7%)
US Comp Sales: +25.9% (est +23.1%)
McDonalds Q221 Earnings:
Revenue: USD5.89B (est USD5.57B)
Adj EPS: USD2.37 (est USD2.11)
Comp Sales: +40.5% (est +38.7%)
US Comp Sales: +25.9% (est +23.1%)
⚡️🇺🇸#TEVA #отчетность
Teva Reports Second Quarter 2021 Financial Results
Revenues of $3.9 billion
GAAP diluted EPS of $0.19
Non-GAAP diluted EPS of $0.59
Cash flow generated from operating activities of $218 million
Free cash flow of $625 million
2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed:
Teva Reports Second Quarter 2021 Financial Results
Revenues of $3.9 billion
GAAP diluted EPS of $0.19
Non-GAAP diluted EPS of $0.59
Cash flow generated from operating activities of $218 million
Free cash flow of $625 million
2021 revenue outlook revised lower to reflect ongoing impact of COVID-19; all other key components reaffirmed:
⚡️🇺🇸#BMY #отчетность
Bristol-Myers Squibb Q221 Earnings:
Revenue: USD11.70B (est USD11.27B)
Adj EPS: USD1.93 (est USD1.89)
Still Sees FY Adj EPS: USD7.35 To USD7.55
Sees FY Gross Margin: 79%
Sees FY Revenue Rising In High Single Digits
Bristol-Myers Squibb Q221 Earnings:
Revenue: USD11.70B (est USD11.27B)
Adj EPS: USD1.93 (est USD1.89)
Still Sees FY Adj EPS: USD7.35 To USD7.55
Sees FY Gross Margin: 79%
Sees FY Revenue Rising In High Single Digits
⚡️🇺🇸#GD #отчетность
General Dynamics Q221 Earnings:
Revenue: USD9.2B (est USD9.31B)
Adj EPS: USD2.61 (est USD2.54)
Backlog: USD89.25B +7.9% Y/Y
Aerospace Revenue: USD1.62B (est USD1.77B
Combat Systems Revenue: USD1.90B (est USD1.78B)
General Dynamics Q221 Earnings:
Revenue: USD9.2B (est USD9.31B)
Adj EPS: USD2.61 (est USD2.54)
Backlog: USD89.25B +7.9% Y/Y
Aerospace Revenue: USD1.62B (est USD1.77B
Combat Systems Revenue: USD1.90B (est USD1.78B)
⚡️🇺🇸#SHOP #отчетность
Shopify Q221 Earnings:
Revenue: USD1.12B (est USD1.05B)
Adj EPS: USD2.24 (est USD0.98)
Gross Merchandise Volume: USD42.2B (est USD40.68B)
Shopify Q221 Earnings:
Revenue: USD1.12B (est USD1.05B)
Adj EPS: USD2.24 (est USD0.98)
Gross Merchandise Volume: USD42.2B (est USD40.68B)
⚡️🇺🇸#CME #отчетность
CME Q2
Non-GAAP EPS of $1.64 beats by $0.03;
GAAP EPS of $1.42 misses by $0.05.
Revenue of $1.18B (flat Y/Y) beats by $10M.
CME Q2
Non-GAAP EPS of $1.64 beats by $0.03;
GAAP EPS of $1.42 misses by $0.05.
Revenue of $1.18B (flat Y/Y) beats by $10M.
⚡️🇺🇸#GRMN #отчетность
Garmin Q2
Non-GAAP EPS of $1.68 beats by $0.43;
GAAP EPS of $1.64 beats by $0.41.
Revenue of $1.33B (+52.9% Y/Y) beats by $230M.
Garmin Q2
Non-GAAP EPS of $1.68 beats by $0.43;
GAAP EPS of $1.64 beats by $0.41.
Revenue of $1.33B (+52.9% Y/Y) beats by $230M.
⚡️🇷🇺#NVTK #отчетность
ЧИСТАЯ ПРИБЫЛЬ НОВАТЭКА ПО МСФО ЗА I ПОЛУГОДИЕ СОСТАВИЛА 164,4 МЛРД РУБ ПРОТИВ 10,9 МЛРД РУБ ГОДОМ РАНЕЕ – КОМПАНИЯ - ПРАЙМ
КАПЗАТРАТЫ НОВАТЭКА В I ПОЛУГОДИИ СОСТАВИЛИ 88,8 МЛРД РУБ ПРОТИВ 102,5 МЛРД РУБ ГОДОМ РАНЕЕ
ЧИСТАЯ ПРИБЫЛЬ НОВАТЭКА ПО МСФО ЗА I ПОЛУГОДИЕ СОСТАВИЛА 164,4 МЛРД РУБ ПРОТИВ 10,9 МЛРД РУБ ГОДОМ РАНЕЕ – КОМПАНИЯ - ПРАЙМ
КАПЗАТРАТЫ НОВАТЭКА В I ПОЛУГОДИИ СОСТАВИЛИ 88,8 МЛРД РУБ ПРОТИВ 102,5 МЛРД РУБ ГОДОМ РАНЕЕ
⚡️🇬🇧#GSK #отчетность
GlaxoSmithKline Q221 Earnings:
Revenue: GBP8.09B (est GBP7.56B)
Adj EPS: 28.1Pence (est GBP19.9 Pence)
Confident In 2021 EPS Guidance And Reconfirm 2022 Outlook
Dividend Of 19p/Share Declared For Q2 2021. Continue To Expect 80p/Share For 2021
GlaxoSmithKline Q221 Earnings:
Revenue: GBP8.09B (est GBP7.56B)
Adj EPS: 28.1Pence (est GBP19.9 Pence)
Confident In 2021 EPS Guidance And Reconfirm 2022 Outlook
Dividend Of 19p/Share Declared For Q2 2021. Continue To Expect 80p/Share For 2021
⚡️🇺🇸#MCO #отчетность
Moody's Q2
Non-GAAP EPS of $3.22 beats by $0.45;
GAAP EPS of $3.07 beats by $0.45.
Revenue of $1.55B (+8.4% Y/Y) beats by $60M.
Moody's Q2
Non-GAAP EPS of $3.22 beats by $0.45;
GAAP EPS of $3.07 beats by $0.45.
Revenue of $1.55B (+8.4% Y/Y) beats by $60M.
⚡️🇺🇸#TLRY #отчетность
Tilray, Inc. reported Q1 EPS of $0.18, versus ($0.39) reported last year. Revenue for the quarter came in at $142.2 million, versus $113.54 million reported last year.
Cannabis Rev $53.7M +38% y/y
- Distribution Rev $66.8M +47% y/y
- Adj EBITDA $12.3M v $3.2M y/y
- Gross margin 16% v 24% y/y
Tilray, Inc. reported Q1 EPS of $0.18, versus ($0.39) reported last year. Revenue for the quarter came in at $142.2 million, versus $113.54 million reported last year.
Cannabis Rev $53.7M +38% y/y
- Distribution Rev $66.8M +47% y/y
- Adj EBITDA $12.3M v $3.2M y/y
- Gross margin 16% v 24% y/y